CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
达沙替尼用于治疗阿基仑赛输注后难治性免疫效应细胞相关神经毒性综合征：1 例病例报告
英文原题：Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report.
查看英文原题
Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已成为治疗难治性血液系统恶性肿瘤的成熟方法。细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）仍是CAR-T 治疗的重要关注点，尤其是在治疗选择有限的难治病例中。我们报告一例患者接受axicabtagene ciloleucel输注后发生重度、类固醇难治性ICANS。尽管接受anakinra、大剂量甲泼尼龙和鞘内化疗，临床症状仍未改善。仅在加入dasatinib作为第四线治疗后，患者ICANS才有所改善，提示该药物可能有益于管理CAR-T 治疗后难治性神经毒性。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy is a well-established approach for refractory hematological malignancies. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain a major concern of CAR T-cell therapy, particularly in refractory cases where therapeutic options are limited.
We report a case of severe, steroid-refractory ICANS following axicabtagene ciloleucel infusion. Despite treatment with anakinra, high-dose methylprednisolone, and intrathecal chemotherapy, no clinical improvement was observed. Only after dasatinib introduction as a fourth-line treatment did the patient show an improvement in ICANS, suggesting the potential benefit of this agent in the management of refractory neurotoxicity after CAR T-cells.
论文信息
- 作者
- Llata-Ortega J、Pau-Parra A、Alonso-Martínez C、García-Roche A、Carpio C、Barba P、Murillo-Florez I、Iacoboni G
- 第一作者单位
- Pharmacy Department, Vall d'Hebron University Hospital, Barcelona, Spain.Spain
- 通讯作者单位
- Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.Spain
- 文献类型
- 病例报告
- 期刊
- European journal of haematology2025 Dec
- 原文标识
- PubMed 40954138 · DOI 10.1111/ejh.70038